Braftovi 50 mg hard capsules
Sponsors
Pfizer Inc., Grupo Espanol Multidisciplinar De Melanoma, Universita' Degli Studi Di Torino
Conditions
MelanomaNon Small Cell Lung CancerNon-small Cell Lung CancerSolid tumors
Phase 2
C4221008 - A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung Cancer
CompletedCTIS2024-515929-28-00
Start: 2019-08-02End: 2025-08-14Target: 59Updated: 2025-08-19
Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlimab in patients with BRAF mutated melanoma and symptomatic brain metastases.
RecruitingCTIS2024-513375-40-00
Start: 2025-05-16Target: 33Updated: 2025-11-25
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:”
“A multi-arms prospective, randomized phase II study to evaluate the best sequential
therapeutic strategis in patients with metastatic non-small cell lung cancer harboring
targetable genomic driver alterations”
Not yet recruitingCTIS2026-525268-16-00
Target: 962Updated: 2026-10-19